Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-10-27
2009-11-24
Desai, Anand U (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S300000
Reexamination Certificate
active
07622437
ABSTRACT:
Tissue Factor (natural or recombinant truncated) can be incorporated into stable, soluble nanoscale particles so that activity is maintained. These particles can be used as a reagent in prothrombin clotting time assays or they can be used in therapeutic compositions for use in humans or animals. Therapeutic settings can include supplementation in the case of a genetic deficiency, uncontrolled bleeding, surgical incisions or seepage, thrombocytopenia, soft tissue trauma or other trauma, to effect tumor regression or to inhibit tumor growth.
REFERENCES:
patent: 5374617 (1994-12-01), Morrissey et al.
patent: 5883078 (1999-03-01), Seelich et al.
patent: 6132729 (2000-10-01), Thorpe et al.
patent: 6172262 (2001-01-01), McQuade et al.
patent: 6248353 (2001-06-01), Singh
patent: 7048949 (2006-05-01), Sligar et al.
patent: 7083958 (2006-08-01), Sligar et al.
patent: 2004/0053384 (2004-03-01), Sligar et al.
patent: 2005/0152984 (2005-07-01), Sligar et al.
patent: 2005/0182243 (2005-08-01), Sligar et al.
patent: 2006/0211092 (2006-09-01), Sligar et al.
patent: 2006/0211093 (2006-09-01), Sligar et al.
patent: WO 93/17031 (1993-09-01), None
patent: WO 00/75187 (2000-12-01), None
patent: WO 01/02551 (2001-01-01), None
patent: WO 02/40501 (2002-05-01), None
Norledge, B. et al., “The Tissue Factor/Factor VIIa/Factor Xa Complex: A Model Built by Docking and Site-Directed Mutagenesis”, Proteins: Structure, Function, and Genetics 53: 640-648 (2003).
Hathcock, J. et al., “Phospholipid Regulates the Activation of Factor X by Tissue Factor/Factor VIIa (TF/VIIa) via Substrate and Product Interactions”, Biochemistry 44: 8187-8197 (2005).
Alam et al. (2005) “Hemorrhage Control in the Battlefield: Role of New Hemostatic Agents,”Mil. Med. 170:63-69.
Altenburg et al. (2007) “Apolipoprotein E Precursor [Homo sapiens],” NCBI Accession No. NP—000032.
Amarante et al. (1999) “Hemoglobin, Beta [Bos Taurus],” NCBI Accession No. NP—776342.
Armstrong et al. (1990) “The Active Site of Membrane-Bound Meizothrombin. A Fluorescence Determination of Its Distance from the Phospholipid Surface and Its Conformational Sensitivity to Calcium and Factor Va,”J. Biol. Chem. 265:6210-6218.
Atkinson et al. (1986) “Recombinant Lipoproteins: Implications for Structure and Assembly of Native Lipoproteins,”Ann. Rev. Biophys. Chem. 15:403-456.
Bach et al. (1986) “Factor VII Binding to Tissue Factor in Reconstituted Phospholipid Vesicles: Induction of Cooperativity by Phosphatidylserine,”Biochemistry25:4007-4020.
Bakker et al. (1982) “Phospholipid Substitution of the Purple Membrane,”Methods Enzymol. 88:26-30.
Barnes et al. (1999) “A Review of Central 5-HT Receptors and Their Function,”Neuropharmacol. 38(8):1083-1152.
Bayburt et al. (May 2002) “Single-Molecule Height Measurements on Microsomal Cytochrome P450 in Nanometer-Scale Phospholipid Bilayer Disks,”Proc. Nat. Acad. Sci. USA99:6725-6730.
Bayburt et al. (Nov. 2003) “Self-Assembly of Single Integral Membrane Proteins into Soluble Nanoscale Phospholipid Bilayers,”Protein Science12:2476-2481.
Bayburt et al. (Jul. 18, 2002) “Self-Assembly of Discoidal Phospholipid Bilayer Nanoparticles with Membrane Scaffold Proteins,”Nano Lett. 2(8):853-856.
Bayburt et al. (1998) “Reconstitution and Imaging of a Membrane Protein in a Nanometer-Size Phospholipid Bilayer,”J. Struct. Biol. 123:37-44.
Bayburt et al. (Jun. 2000) “Single Molecule Height Measurements on a Membrane Protein in Nanometer-Scale Phospholipid Bilayer Disks,”Langmuir16(14):5993-5997.
Bayley et al. (2001) “Delipidation, Renaturation, and Reconstitution of Bacberiorhodopsin,”Methods Enzymol. 88:74-81.
Bergeron et al. (1995) “Apolipoprotein A-I Conformation in Reconstituted Discoidal Lipoproteins Varying in Phospholipid and Cholesterol Content,”J. Biol. Chem. 270:27429-27438.
Bergeron et al. (1997) “Characterization of Human Apolipoprotein A-I Expressed inEscherichia coli,” Biochim. Biophys. Acta1344:139-152.
Billy et al. (1995) “Prothombin Contributes to the Assembly of the Factor Va-Factor Xa Complex at Phosphatidylserine-Containing Phospholipid Membranes,”J. Biol. Chem.270:26883-26889.
Boguski et al. (1986) “On Computer-Assisted Analysis of Biological Sequences: Proline Punctuation, Consensus Sequences, and Apolipoprotein Repeats,”J. Lipid Res. 27:1011-1034.
Borhani, et al. (1997) “Crystal Structure of Truncated Human Apolipoprotein A-I Suggests a Lipid-Bound Conformation,”Proc. Nat. Acad. Sci. USA94:12291-12296.
Bolanos-Garcia et al. (2003) “On the Structure and Function of Apolipoproteins: More than a Family of Lipid-Binding Proteins,”Prop. Biophys. Mol. Biol. 83:47-68.
Brekken et al. (2001) “Vascular Endothelial Growth Factor and Vascular Targeting of Solid Tumors,”Anticancer Res. 21:4221-4230.
Brouillette et al. (1984) “Structural Studies of Apolipoprotein A-I/Phosphatidylcholine Recombinants by High-Filed Proton NMR, Nondenaturing Gradient Gel Electrophoresis, and Electron Microscopy,”Biochemistry23:359-397.
Brouillette et al. (2001) “Structural Models of Human Apolipoprotein A-I: A Critical Analysis and Review,”Biochim. Biophys. Acta1531:4-46.
Bruhn et al. (1991) “An Approach to the Functional Analysis of Lecithin-Cholesterol Acryltransferase. Activation by Recombinant Normal and Mutagenized Apolipoprotein Al,”Biological Chem. Hoppee-Seyler372(3):225-234.
Burgess et al. (Nov. 2, 1999) “Deletion of the C-Terminal Domain of Apolipoprotein A-I Impairs Cell Surface Binding and Lipid Efflux in Macrophage,”Biochemistry38(44):14524-14533.
Cao et al. (Feb. 10, 2003) “Bispecific Antibody Conjugates in Therapeutics,”Adv. Drug Del. Rev. 55(2):171-197.
Carlson et al. (Mar. 2000) “Nanopatterning Phospholipid Bilayers,”Langmuir16(8):3927-3931.
Carlson et al. (Sep. 1997) “Imaging and Manipulation of High-Density Lipoproteins,”Biophys. J. 73:1184-1189.
Carr et al. (1998) “Recombinant Factor VIIa: Clinical Applications for an Intravenous Hemostatic Agent With Broab-Spectrum Potential,”Expert Rev. Cardiovasc. Ther. 2:661-674.
Carter (2001) “Improving the Efficacy of Antibody-Based Cancer Therapies,”Nat. Rev. Cancer1:118-129.
Chen et al. (2002) “Amino Acids in SRS1 and SRS6 are Critical for Furanocoumarin Metabolism by CYP6B1v1, a Cytochrome P450 Monooxygenase,”Insect Mol. Biol. 11:175-186.
Chou et al. (Jan. 15, 1974) “Conformational Parameters for Amino Acids in Helical, β-Sheet, and Random Coil Regions Calculated from Proteins,”Biochemistry13(2):211-222.
Chou et al. (1978) “Empirical Predictions of Protein Conformation,”Ann. Rev. Biochem. 47:251-278.
Civjan et al. (2003) “Direct Solubilization of Heterologously Expressed Membrane Proteins by Incorporation into Nanoscale Lipid Bilayers,”BioTechniques35:556-563.
Dalton et al. (Sep. 15, 1993) “Structural and Functional Domains of Apolipoprotein A-I Within High Density Lipoproteins,”J. Biol. Chem. 268(26):19274-19283.
De Donato et al. (2003) “Myoglobin [Bos Taurus],” NCBI Accession No. NP—776306.
Dencher et al. (1982) “Preparation and Properties of Monomeric Bacteriorhodosin,”Methods Enzymol. 88:5-10.
Denisov et al. (Mar. 2004) “Directed Self-Assembly of Monodisperse Phospholipid Bilayer Nanodiscs with Controlled Size,”J. Am. Chem. Soc. 126(11):3477-3487.
Drake, D.S. et al. (1989) “Selective Cellular Expression of Tissue Factor in Human Tissues. Implications for Disorders of Hemostasis and Thrombosis,”Am. J. Pathol. 134:1087-1097.
Duan et al. (Apr. 15, 2004) “Co-Incorporation of Heterologously-ExpressedArabidopsisCytochrome P450 and P450 Reductase into Soluble Nanoscale Lipid Bilayers,”A
Morrissey James H.
Pureza Vincent S.
Sligar Stephen G.
Desai Anand U
Greenlee Winner and Sullivan P.C.
The Board of Trustees of the University of Illinois
LandOfFree
Tissue factor compositions and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tissue factor compositions and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tissue factor compositions and methods will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4062685